Oncotect vs PetDx and other Cancer Screening Methods

Oncotect is a cutting-edge company that offers a non-invasive, multi-cancer screening test for dogs. The test is designed to deliver a range of benefits that are not available with other cancer screening options, such as PetDx and Volition. These benefits include multi-cancer detection, high accuracy, convenience, cost-effectiveness, early screening, and non-invasiveness.

PetDx is a San Diego-based molecular diagnostics company that uses human liquid biopsy technology to detect cancer in dogs. Its flagship product, OncoK9, enables veterinarians to detect cancer in dogs with a blood draw. However, this test is invasive (15 ml of blood draw) and its accuracy is limited, with a sensitivity of 54.7% and a specificity of 98.4% among 30 canine cancer types. Additionally, the high cost of the test ($1,000 at retail) can make it prohibitively expensive for many pet owners.

Volition is an epigenetics company that is developing blood tests to help diagnose a range of cancers and other diseases. Its Nu.Q Vet Cancer Screening Test uses an Enzyme-Linked Immunosorbent Assay (ELISA) based screening blood test, which is designed to streamline the diagnostic process for older or at-risk dogs. However, this test is also invasive (blood draw) and currently detects lymphoma (77% sensitivity), hemangiosarcoma (82% sensitivity), and histiocytic sarcoma (54% sensitivity).

In comparison, Oncotect's test offers a range of benefits that are not available with other cancer screening options. This test can detect different types of cancers, including lymphoma, hemangiosarcoma, mast cell tumor, and melanoma, with a high accuracy of 85% sensitivity and 96% specificity among the four most common cancer types. The test is also convenient, requiring only a simple urine sample, and cost-effective, with a retail cost of $199 compared to traditional methods that can cost $700 or more. Additionally, this test allows for early screening, before any clinical signs of cancer appear, and is non-invasive, with no needle necessary.

In conclusion, Oncotect's test is the only cancer screening option that can deliver all six areas of benefits, while other competitors, such as PetDx and Volition, can only deliver three or four benefits at most. By offering a non-invasive, multi-cancer screening test that is both convenient and cost-effective, Oncotect is providing pet owners with a new, cutting-edge solution for detecting cancer in their furry friends.